Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Cytosorbents Corporation (CTSO) had Stock-Based Compensation of $2.77M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$37.06M |
|
$-8.20M |
|
$10.57M |
|
$26.49M |
|
$51.81M |
|
$-14.75M |
|
$6.15M |
|
$-8.60M |
|
$-8.60M |
|
$-8.20M |
|
$-8.20M |
|
$-8.20M |
|
$-8.20M |
|
$-14.75M |
|
$-12.30M |
|
62.23M |
|
62.23M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$20.63M |
|
$7.82M |
|
$23.55M |
|
$44.18M |
|
$9.71M |
|
$16.67M |
|
$28.57M |
|
$38.28M |
|
$5.90M |
|
$2.68M |
|
$5.90M |
|
62.80M |
|
| Cash Flow Statement Financials | |
$-12.38M |
|
$-0.41M |
|
$9.31M |
|
$9.76M |
|
$7.77M |
|
$-1.99M |
|
|
Stock-Based Compensation |
$2.77M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.13 |
|
-- |
|
-- |
|
0.74 |
|
2.82 |
|
71.48% |
|
-39.79% |
|
-39.79% |
|
-33.18% |
|
-23.20% |
|
-22.12% |
|
$-12.46M |
|
-- |
|
-- |
|
-- |
|
0.84 |
|
2.00 |
|
4.91 |
|
74.35 |
|
-138.88% |
|
-306.24% |
|
-18.56% |
|
-36.32% |
|
$0.09 |
|
$-0.20 |
|
$-0.20 |
|